ATE297731T1 - Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol - Google Patents

Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol

Info

Publication number
ATE297731T1
ATE297731T1 AT99911307T AT99911307T ATE297731T1 AT E297731 T1 ATE297731 T1 AT E297731T1 AT 99911307 T AT99911307 T AT 99911307T AT 99911307 T AT99911307 T AT 99911307T AT E297731 T1 ATE297731 T1 AT E297731T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
treatment
clioquinol
metal chelators
Prior art date
Application number
AT99911307T
Other languages
English (en)
Inventor
Ashley L Bush
Xudong Huang
Craig S Atwood
Rudolph E Tanzi
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE297731T1 publication Critical patent/ATE297731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT99911307T 1998-03-11 1999-03-11 Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol ATE297731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/038,154 US6323218B1 (en) 1998-03-11 1998-03-11 Agents for use in the treatment of Alzheimer's disease
PCT/US1999/005291 WO1999045907A2 (en) 1998-03-11 1999-03-11 Metal chelators for use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE297731T1 true ATE297731T1 (de) 2005-07-15

Family

ID=21898356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911307T ATE297731T1 (de) 1998-03-11 1999-03-11 Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol

Country Status (8)

Country Link
US (2) US6323218B1 (de)
EP (1) EP1061923B1 (de)
JP (1) JP2002506020A (de)
AT (1) ATE297731T1 (de)
AU (1) AU752236B2 (de)
CA (1) CA2323458C (de)
DE (1) DE69925816T2 (de)
WO (1) WO1999045907A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) * 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE60037768T2 (de) * 1999-05-27 2009-01-15 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit Superoxid-Dismutase Imitatoren
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
AUPQ180499A0 (en) * 1999-07-23 1999-08-19 Biomolecular Research Institute Limited Beta-amyloid peptide inhibitors
EP1222566A1 (de) * 1999-09-23 2002-07-17 Chroma Graphics, Inc. Verfahren und vorrichtung zum beschreiben und simulieren komplexer systeme
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
ATE555782T1 (de) 2002-03-08 2012-05-15 Philera New Zealand Ltd Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
EP1531827A4 (de) * 2002-05-24 2009-07-08 Univ Michigan Kupfer-verringernde behandlung für entzündliche und fibrotische erkrankungen
US20070248689A1 (en) * 2002-05-24 2007-10-25 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
WO2004007673A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
CN1774267A (zh) * 2003-01-22 2006-05-17 综合医院有限公司 与淀粉样物质结合的金属螯合剂
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
EP1685837A4 (de) * 2003-11-12 2009-03-25 Lead Chem Co Ltd Gehirnschutzmittel vom perkutanen absorptionstyp
AU2004298393A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
ES2449066T3 (es) 2004-07-19 2014-03-18 Philera New Zealand Limited Síntesis de trietilentetraminas
AU2005271452B2 (en) 2004-08-03 2011-11-03 Vtv Therapeutics Llc RAGE fusion proteins and methods of use
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
WO2006041874A2 (en) * 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
CA2596371A1 (en) * 2005-01-31 2006-08-03 Riken Agent for control degranulation reaction and cytokine production
CA2632697C (en) * 2005-11-09 2016-01-05 Protemix Corporation Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
EP1963786B1 (de) * 2005-12-23 2013-07-24 GCoder Systems AB Positionierungsmuster
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
US20130178536A1 (en) * 2006-04-25 2013-07-11 Stc.Unm Substituted cis- and trans-stilbenes as therapeutic agents
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
US8338089B2 (en) * 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
US20090131857A1 (en) * 2007-11-20 2009-05-21 Mark Geiger Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2016005992A1 (en) * 2014-07-11 2016-01-14 Council Of Scientific And Industrial Research SUBSTITUTED NAPHTHO[2,1-b][1,10]PHENANTHROLINE BASED FLUORESCENT DYES AND APPLICATION THEREOF
WO2019067782A1 (en) * 2017-09-28 2019-04-04 University Of Massachusetts COMBINED TREATMENT OF NEUROPSYCHIATRIC DISORDERS
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
CA3110582A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110493A (en) 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5677330A (en) 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
WO1994004167A1 (en) 1991-02-26 1994-03-03 THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Metal-based formulations with high microbicidal efficiency valuable for disinfection and sterilization
GB9108080D0 (en) 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
GB9123937D0 (en) * 1991-11-11 1992-01-02 Framo Dev Ltd Metering device for a multiphase fluid flow
AU669493B2 (en) 1991-11-12 1996-06-13 University Of Melbourne, The A method for assaying and treating Alzheimer's disease
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
GB9211779D0 (en) 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
US5357636A (en) * 1992-06-30 1994-10-25 Dresdner Jr Karl P Flexible protective medical gloves and methods for their use
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
AU6580494A (en) 1994-05-11 1995-12-05 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
WO1997009976A2 (en) 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
NZ334124A (en) * 1996-08-13 2000-10-27 P Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
DE19648272A1 (de) * 1996-11-21 1998-05-28 Emitec Emissionstechnologie Verfahren und Vorrichtung zur Bestimmung einer Zelldichte eines Wabenkörpers, insbesondere für einen Abgaskatalysator
JP2001514661A (ja) * 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定
EP1007040B1 (de) 1997-08-21 2002-05-08 P.N. Gerolymatos S.A. Verwendung von phanquinon zur behandlung von alzheimer's krankheit
US5980914A (en) * 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
CA2305732A1 (en) 1997-10-06 1999-04-15 The General Hospital Corporation Methods for screening drugs to predict tardive dyskinesia
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
CA2323458C (en) 2008-01-29
CA2323458A1 (en) 1999-09-16
DE69925816D1 (de) 2005-07-21
AU752236B2 (en) 2002-09-12
EP1061923A2 (de) 2000-12-27
WO1999045907A9 (en) 2000-11-09
HK1033907A1 (en) 2001-10-05
US20020082273A1 (en) 2002-06-27
JP2002506020A (ja) 2002-02-26
AU2998199A (en) 1999-09-27
DE69925816T2 (de) 2005-12-22
US6323218B1 (en) 2001-11-27
WO1999045907A3 (en) 2000-04-06
WO1999045907A2 (en) 1999-09-16
EP1061923B1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
ATE297731T1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
ATE222744T1 (de) Formulierungen und verfahren zur reduzierung von hautreizung
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
ATE371475T1 (de) Methoden zur behandlung der hautpigmentierung
ATE299890T1 (de) Inhibitoren von gamma-secretase
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BG105112A (bg) Средство с антидепресивно действие
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE553415T1 (de) Lichtempfindliche polyimid-precursor- zusammensetzungen
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
DE69924676D1 (de) Rotor zur Behandlung von geschmolzenem Metall
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE67992T1 (de) In 4-stellung durch stickstoff substituierte isochinolinolverbindungen mit cardiotonischen, die wirkung von phosphodiesterase-fraktion-iii inhibierenden und/oder renal vasodilatierenden eigenschaften.
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE222298T1 (de) Verwendung von zinklegierungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties